Intraventricular Urokinase for Intraventricular Hemorrhage (IVH)» Previous Study || » Next Study » back to Research Principal Investigator:Dr. Neil Naff Department of Neurosurgery Johns Hopkins Medical Center Site Investigator:Dr. Stephan MayerDepartment of Neurology Division of Critical Care Neurology This is a randomized, double-blinded, placebo-controlled multicenter clinical trial to evaluate the effectiveness of intraventricular administration of urokinase on the resolution of intraventricular hemorrhage associated with intracerebral or aneurysmal subarachnoid hemorrhage. Potential subjects will include patients ages 18- 75, admitted to the NICU for an intraventricular hemorrhage (IVH) who have obstructive hydrocephalus requiring an intraventricular catheter (IVC). Patients will receive intraventricular injection of urokinase or placebo every 12 hours until IVH clot resolution, as confirmed by CT scan. The primary outcome measures are (1) percent rate of intraventricular blood clot resolution as determined by serial CT scans, (2) duration of external ventricular drainage, and (3) the incidence of communicating hydrocephalus at 30 days. Long-term functional outcome will be assessed through a 15 minute telephone interview at 30 days post-bleed, using the Barthel and Rankin Scales. |
 About the Division of Neurocritical Care || Our Doctors || Patient Information || Education || Research || In The News || Contact Us || Sitemap Copyright © 2008 Division of Neurocritical Care, Department of Neurology, Columbia University Medical Center, New York || The Neurological Institute of New York Affiliated with New York-Presbyterian Hospital || Last updated: September 27, 2011 | Comments |